Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 63

1.

Validity of ICD-9 and ICD-10 codes used to identify acute liver injury: A study in three European data sources.

Forns J, Cainzos-Achirica M, Hellfritzsch M, Morros R, Poblador-Plou B, Hallas J, Giner-Soriano M, Prados-Torres A, Pottegård A, Cortés J, Castellsagué J, Jacquot E, Deltour N, Perez-Gutthann S, Pladevall M.

Pharmacoepidemiol Drug Saf. 2019 Jul;28(7):965-975. doi: 10.1002/pds.4803. Epub 2019 Jun 6.

2.

Use of aclidinium did not increase the risk of death in a noninterventional cohort study in the Clinical Practice Research Datalink (CPRD), United Kingdom.

Rebordosa C, Aguado J, Plana E, Thomas S, Frances A, Lei A, García-Gil E, Nuevo J, Perez-Gutthann S, Castellsague J.

Respir Med. 2019 Jun;152:37-43. doi: 10.1016/j.rmed.2019.04.018. Epub 2019 Apr 26.

PMID:
31128608
3.

Risk of Acute Liver Injury in Agomelatine and Other Antidepressant Users in Four European Countries: A Cohort and Nested Case-Control Study Using Automated Health Data Sources.

Pladevall-Vila M, Pottegård A, Schink T, Reutfors J, Morros R, Poblador-Plou B, Timmer A, Forns J, Hellfritzsch M, Reinders T, Hägg D, Giner-Soriano M, Prados-Torres A, Cainzos-Achirica M, Hallas J, Brandt L, Cortés J, Aguado J, Perlemuter G, Falissard B, Castellsagué J, Jacquot E, Deltour N, Perez-Gutthann S.

CNS Drugs. 2019 Apr;33(4):383-395. doi: 10.1007/s40263-019-00611-9.

4.

Risk of acute myocardial infarction during use of individual NSAIDs: A nested case-control study from the SOS project.

Masclee GMC, Straatman H, Arfè A, Castellsague J, Garbe E, Herings R, Kollhorst B, Lucchi S, Perez-Gutthann S, Romio S, Schade R, Schink T, Schuemie MJ, Scotti L, Varas-Lorenzo C, Valkhoff VE, Villa M, Sturkenboom MCJM.

PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746. eCollection 2018.

5.

Effectiveness of risk minimization measures for the use of cilostazol in United Kingdom, Spain, Sweden, and Germany.

Castellsague J, Poblador-Plou B, Giner-Soriano M, Linder M, Scholle O, Calingaert B, Bui C, Arana A, Laguna C, Gonzalez-Rubio F, Roso-Llorach A, Prados-Torres A, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2018 Sep;27(9):953-961. doi: 10.1002/pds.4584. Epub 2018 Jul 25.

6.

GOLD assessment of COPD severity in the Clinical Practice Research Datalink (CPRD).

Rebordosa C, Plana E, Aguado J, Thomas S, García-Gil E, Perez-Gutthann S, Castellsague J.

Pharmacoepidemiol Drug Saf. 2019 Feb;28(2):126-133. doi: 10.1002/pds.4448. Epub 2018 May 8.

PMID:
29740896
7.

Use of Topical Tacrolimus and Topical Pimecrolimus in Four European Countries: A Multicentre Database Cohort Study.

Kuiper JG, van Herk-Sukel MPP, Castellsague J, Pottegård A, Berglind IA, Dedman D, Gutierrez L, Calingaert B, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S.

Drugs Real World Outcomes. 2018 Jun;5(2):109-116. doi: 10.1007/s40801-018-0133-1.

8.

A cohort study on the risk of lymphoma and skin cancer in users of topical tacrolimus, pimecrolimus, and corticosteroids (Joint European Longitudinal Lymphoma and Skin Cancer Evaluation - JOELLE study).

Castellsague J, Kuiper JG, Pottegård A, Anveden Berglind I, Dedman D, Gutierrez L, Calingaert B, van Herk-Sukel MP, Hallas J, Sundström A, Gallagher AM, Kaye JA, Pardo C, Rothman KJ, Perez-Gutthann S.

Clin Epidemiol. 2018 Mar 13;10:299-310. doi: 10.2147/CLEP.S146442. eCollection 2018.

9.

S100A7: from mechanism to cancer therapy.

Padilla L, Dakhel S, Adan J, Masa M, Martinez JM, Roque L, Coll T, Hervas R, Calvis C, Llinas L, Buenestado S, Castellsague J, Messeguer R, Mitjans F, Hernandez JL.

Oncogene. 2017 Dec 7;36(49):6749-6761. doi: 10.1038/onc.2017.283. Epub 2017 Aug 21.

PMID:
28825725
10.

Characterization of new users of cilostazol in the UK, Spain, Sweden, and Germany.

Castellsague J, Perez-Gutthann S, Calingaert B, Bui C, Varas-Lorenzo C, Arana A, Prados-Torres A, Poblador-Plou B, Gonzalez-Rubio F, Giner-Soriano M, Roso-Llorach A, Linder M, Citarella A, Scholle O, Blenk T, Garbe E.

Pharmacoepidemiol Drug Saf. 2017 Jun;26(6):615-624. doi: 10.1002/pds.4167. Epub 2017 Jan 30.

11.

Acute pain: a multifaceted challenge - the role of nimesulide.

Kress HG, Baltov A, Basiński A, Berghea F, Castellsague J, Codreanu C, Copaciu E, Giamberardino MA, Hakl M, Hrazdira L, Kokavec M, Lejčko J, Nachtnebl L, Stančík R, Švec A, Tóth T, Vlaskovska MV, Woroń J.

Curr Med Res Opin. 2016;32(1):23-36. doi: 10.1185/03007995.2015.1100986. Epub 2015 Oct 15. Review.

PMID:
26414386
12.

Comprehensive establishment and characterization of orthoxenograft mouse models of malignant peripheral nerve sheath tumors for personalized medicine.

Castellsagué J, Gel B, Fernández-Rodríguez J, Llatjós R, Blanco I, Benavente Y, Pérez-Sidelnikova D, García-Del Muro J, Viñals JM, Vidal A, Valdés-Mas R, Terribas E, López-Doriga A, Pujana MA, Capellá G, Puente XS, Serra E, Villanueva A, Lázaro C.

EMBO Mol Med. 2015 May;7(5):608-27. doi: 10.15252/emmm.201404430.

13.

Risk of acute liver injury associated with the use of moxifloxacin and other oral antimicrobials: a retrospective, population-based cohort study.

Kaye JA, Castellsague J, Bui CL, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan S, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S.

Pharmacotherapy. 2014;34(4):336-49. doi: 10.1002/phar.1367. Epub 2013 Nov 5.

14.

Tubers from patients with tuberous sclerosis complex are characterized by changes in microtubule biology through ROCK2 signalling.

Ferrer I, Mohan P, Chen H, Castellsague J, Gómez-Baldó L, Carmona M, García N, Aguilar H, Jiang J, Skowron M, Nellist M, Ampuero I, Russi A, Lázaro C, Maxwell CA, Pujana MA.

J Pathol. 2014 Jul;233(3):247-57. doi: 10.1002/path.4343. Epub 2014 Apr 29. Erratum in: J Pathol. 2016 Jun;239(2):242.

PMID:
24604753
15.

Response to the letter to the editor entitled "diclofenac: increase of myocardial infarctions at low doses?" (PDS 13-0441) authored by K Brune.

Varas-Lorenzo C, Castellsague J, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2014 Mar;23(3):329-30. doi: 10.1002/pds.3563. No abstract available.

PMID:
24596324
16.

Validation of acute liver injury cases in a population-based cohort study of oral antimicrobial users.

Bui CL, Kaye JA, Castellsague J, Calingaert B, McQuay LJ, Riera-Guardia N, Saltus CW, Quinlan SC, Holick CN, Wahl PM, Suzart K, Rothman KJ, Wallander MA, Perez-Gutthann S.

Curr Drug Saf. 2014 Mar;9(1):23-8.

PMID:
24111729
17.

Accuracy of International Classification of Diseases, 9th Revision, Clinical Modification codes for upper gastrointestinal complications varied by position and age: a validation study in a cohort of nonsteroidal anti-inflammatory drugs users in Friuli Venezia Giulia, Italy.

Pisa F, Castellsague J, Drigo D, Riera-Guardia N, Giangreco M, Rosolen V, Clagnan E, Zanier L, Perez-Gutthann S, Barbone F.

Pharmacoepidemiol Drug Saf. 2013 Nov;22(11):1195-204. doi: 10.1002/pds.3504. Epub 2013 Aug 20.

PMID:
23959537
18.

Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Salvo F, Nicotra F, Sturkenboom M, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2013 Jun;22(6):559-70. Review.

19.

Genomic imbalance of HMMR/RHAMM regulates the sensitivity and response of malignant peripheral nerve sheath tumour cells to aurora kinase inhibition.

Mohan P, Castellsague J, Jiang J, Allen K, Chen H, Nemirovsky O, Spyra M, Hu K, Kluwe L, Pujana MA, Villanueva A, Mautner VF, Keats JJ, Dunn SE, Lazaro C, Maxwell CA.

Oncotarget. 2013 Jan;4(1):80-93.

20.

Risk of upper gastrointestinal complications in a cohort of users of nimesulide and other nonsteroidal anti-inflammatory drugs in Friuli Venezia Giulia, Italy.

Castellsague J, Pisa F, Rosolen V, Drigo D, Riera-Guardia N, Giangreco M, Clagnan E, Tosolini F, Zanier L, Barbone F, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2013 Apr;22(4):365-75. doi: 10.1002/pds.3385. Epub 2012 Dec 11.

PMID:
23229866
21.

Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project).

Castellsague J, Riera-Guardia N, Calingaert B, Varas-Lorenzo C, Fourrier-Reglat A, Nicotra F, Sturkenboom M, Perez-Gutthann S; Safety of Non-Steroidal Anti-Inflammatory Drugs (SOS) Project.

Drug Saf. 2012 Dec 1;35(12):1127-46. doi: 10.2165/11633470-000000000-00000. Review.

22.

Clinical burden and incremental cost of fractures in postmenopausal women in the United Kingdom.

Gutiérrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Gitlin M, Robbins S.

Bone. 2012 Sep;51(3):324-31. doi: 10.1016/j.bone.2012.05.020. Epub 2012 Jun 6.

PMID:
22684000
23.

Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer.

Maxwell CA, Benítez J, Gómez-Baldó L, Osorio A, Bonifaci N, Fernández-Ramires R, Costes SV, Guinó E, Chen H, Evans GJ, Mohan P, Català I, Petit A, Aguilar H, Villanueva A, Aytes A, Serra-Musach J, Rennert G, Lejbkowicz F, Peterlongo P, Manoukian S, Peissel B, Ripamonti CB, Bonanni B, Viel A, Allavena A, Bernard L, Radice P, Friedman E, Kaufman B, Laitman Y, Dubrovsky M, Milgrom R, Jakubowska A, Cybulski C, Gorski B, Jaworska K, Durda K, Sukiennicki G, Lubiński J, Shugart YY, Domchek SM, Letrero R, Weber BL, Hogervorst FB, Rookus MA, Collee JM, Devilee P, Ligtenberg MJ, Luijt RB, Aalfs CM, Waisfisz Q, Wijnen J, Roozendaal CE; HEBON; EMBRACE, Easton DF, Peock S, Cook M, Oliver C, Frost D, Harrington P, Evans DG, Lalloo F, Eeles R, Izatt L, Chu C, Eccles D, Douglas F, Brewer C, Nevanlinna H, Heikkinen T, Couch FJ, Lindor NM, Wang X, Godwin AK, Caligo MA, Lombardi G, Loman N, Karlsson P, Ehrencrona H, Wachenfeldt Av; SWE-BRCA, Barkardottir RB, Hamann U, Rashid MU, Lasa A, Caldés T, Andrés R, Schmitt M, Assmann V, Stevens K, Offit K, Curado J, Tilgner H, Guigó R, Aiza G, Brunet J, Castellsagué J, Martrat G, Urruticoechea A, Blanco I, Tihomirova L, Goldgar DE, Buys S, John EM, Miron A, Southey M, Daly MB; BCFR, Schmutzler RK, Wappenschmidt B, Meindl A, Arnold N, Deissler H, Varon-Mateeva R, Sutter C, Niederacher D, Imyamitov E, Sinilnikova OM, Stoppa-Lyonne D, Mazoyer S, Verny-Pierre C, Castera L, de Pauw A, Bignon YJ, Uhrhammer N, Peyrat JP, Vennin P, Fert Ferrer S, Collonge-Rame MA, Mortemousque I; GEMO Study Collaborators, Spurdle AB, Beesley J, Chen X, Healey S; kConFab, Barcellos-Hoff MH, Vidal M, Gruber SB, Lázaro C, Capellá G, McGuffog L, Nathanson KL, Antoniou AC, Chenevix-Trench G, Fleisch MC, Moreno V, Pujana MA.

PLoS Biol. 2011 Nov;9(11):e1001199. doi: 10.1371/journal.pbio.1001199. Epub 2011 Nov 15.

24.

Stroke risk and NSAIDs: a systematic review of observational studies.

Varas-Lorenzo C, Riera-Guardia N, Calingaert B, Castellsague J, Pariente A, Scotti L, Sturkenboom M, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2011 Dec;20(12):1225-36. doi: 10.1002/pds.2227. Epub 2011 Oct 3. Review.

PMID:
21971833
25.

Assessing the RNA effect of 26 DNA variants in the BRCA1 and BRCA2 genes.

Menéndez M, Castellsagué J, Mirete M, Pros E, Feliubadaló L, Osorio A, Calaf M, Tornero E, del Valle J, Fernández-Rodríguez J, Quiles F, Salinas M, Velasco A, Teulé A, Brunet J, Blanco I, Capellá G, Lázaro C.

Breast Cancer Res Treat. 2012 Apr;132(3):979-92. doi: 10.1007/s10549-011-1661-5. Epub 2011 Jul 7.

PMID:
21735045
26.

A mild neurofibromatosis type 1 phenotype produced by the combination of the benign nature of a leaky NF1-splice mutation and the presence of a complex mosaicism.

Fernández-Rodríguez J, Castellsagué J, Benito L, Benavente Y, Capellá G, Blanco I, Serra E, Lázaro C.

Hum Mutat. 2011 Jul;32(7):705-9. doi: 10.1002/humu.21500. Epub 2011 Jun 2.

PMID:
21394830
27.

Study of the incremental cost and clinical burden of hip fractures in postmenopausal women in the United Kingdom.

Gutiérrez L, Roskell N, Castellsague J, Beard S, Rycroft C, Abeysinghe S, Shannon P, Robbins S, Gitlin M.

J Med Econ. 2011;14(1):99-107. doi: 10.3111/13696998.2010.547967. Epub 2011 Jan 11.

PMID:
21222505
28.

Use of long-acting beta-agonists and inhaled steroids in asthma: meta-analysis of observational studies.

Hirst C, Calingaert B, Stanford R, Castellsague J.

J Asthma. 2010 May;47(4):439-46. doi: 10.3109/02770901003605340.

PMID:
20528600
29.

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA.

Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5.

PMID:
20031832
30.

Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S.

Pharmacotherapy. 2009 Dec;29(12):1397-407. doi: 10.1592/phco.29.12.1397.

PMID:
19947799
31.

The use of selective cyclooxygenase-2 inhibitors and the risk of acute myocardial infarction in Saskatchewan, Canada.

Varas-Lorenzo C, Castellsague J, Stang MR, Perez-Gutthann S, Aguado J, Rodriguez LA.

Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1016-25. doi: 10.1002/pds.1815.

PMID:
19718696
32.

Hospitalization for peptic ulcer and bleeding in users of selective COX-2 inhibitors and nonselective NSAIDs with special reference to celecoxib.

Patterson MK, Castellsague J, Walker AM.

Pharmacoepidemiol Drug Saf. 2008 Oct;17(10):982-8. doi: 10.1002/pds.1639.

PMID:
18711705
33.

Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database.

Varas-Lorenzo C, Castellsague J, Stang MR, Tomas L, Aguado J, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2008 Aug;17(8):842-52. doi: 10.1002/pds.1619.

PMID:
18498081
34.

Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.

Roumie CL, Mitchel E, Gideon PS, Varas-Lorenzo C, Castellsague J, Griffin MR.

Pharmacoepidemiol Drug Saf. 2008 Jan;17(1):20-6.

PMID:
17979142
35.

Hepatic disorders in patients treated with COX-2 selective inhibitors or nonselective NSAIDs: a case/noncase analysis of spontaneous reports.

Sanchez-Matienzo D, Arana A, Castellsague J, Perez-Gutthann S.

Clin Ther. 2006 Aug;28(8):1123-1132. doi: 10.1016/j.clinthera.2006.08.014.

PMID:
16982289
36.

Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.

Varas-Lorenzo C, Maguire A, Castellsague J, Perez-Gutthann S.

Pharmacoepidemiol Drug Saf. 2007 Apr;16(4):366-76.

PMID:
16897817
37.

Channeling and prevalence of cardiovascular contraindications in users of cyclooxygenase 2 selective nonsteroidal antiinflammatory drugs.

Mosis G, Stijnen T, Castellsague J, Dieleman JP, van der Lei J, Stricker BH, Sturkenboom MC.

Arthritis Rheum. 2006 Aug 15;55(4):537-42.

38.

Use of oral corticosteroids and the risk of acute myocardial infarction.

Varas-Lorenzo C, Rodriguez LA, Maguire A, Castellsague J, Perez-Gutthann S.

Atherosclerosis. 2007 Jun;192(2):376-83. Epub 2006 Jun 19.

PMID:
16787647
39.

Non-steroidal anti-inflammatory drugs and risk of first hospital admission for heart failure in the general population.

Huerta C, Varas-Lorenzo C, Castellsague J, García Rodríguez LA.

Heart. 2006 Nov;92(11):1610-5. Epub 2006 May 22.

40.

Nonsteroidal anti-inflammatory drugs and risk of ARF in the general population.

Huerta C, Castellsague J, Varas-Lorenzo C, García Rodríguez LA.

Am J Kidney Dis. 2005 Mar;45(3):531-9.

PMID:
15754275
41.

(Unlearned) lessons from John Graunt and Kenneth Rothman: a "CLASSic" example.

Arellano FM, Castellsague J; CLASS.

Clin Ther. 2003 Nov;25(11):2891-6; discussion 2897.

PMID:
14693312
42.

Risk of serious skin disorders among users of oral antifungals: a population-based study.

Castellsague J, García-Rodríguez LA, Duque A, Pérez S.

BMC Dermatol. 2002 Nov 28;2:14. Epub 2002 Nov 28.

43.

One-year efficacy and safety of inhaled formoterol dry powder in children with persistent asthma.

Bensch G, Berger WE, Blokhin BM, Socolovsky AL, Thomson MH, Till MD, Castellsague J, Della Cioppa G; International Study Group on Foradil Evaluation in Pediatric Asthma.

Ann Allergy Asthma Immunol. 2002 Aug;89(2):180-90.

PMID:
12197575
44.

Efficacy of omalizumab, an anti-immunoglobulin E antibody, in patients with allergic asthma at high risk of serious asthma-related morbidity and mortality.

Holgate S, Bousquet J, Wenzel S, Fox H, Liu J, Castellsague J.

Curr Med Res Opin. 2001;17(4):233-40.

PMID:
11922396
45.

A cohort study on the risk of acute liver injury among users of ketoconazole and other antifungal drugs.

García Rodríguez LA, Duque A, Castellsague J, Pérez-Gutthann S, Stricker BH.

Br J Clin Pharmacol. 1999 Dec;48(6):847-52.

46.

Characteristics of users of inhaled long-acting beta 2-agonists in a southern European population.

Castellsague J, Garcia-Rodríguez LA, Pérez-Gutthann S, Agostinis L, Cattaruzi C, Troncon MG.

Respir Med. 1999 Oct;93(10):709-14.

47.
48.

Prediction equations for plethysmographic lung volumes.

Roca J, Burgos F, Barberà JA, Sunyer J, Rodriguez-Roisin R, Castellsagué J, Sanchis J, Antóo JM, Casan P, Clausen JL.

Respir Med. 1998 Mar;92(3):454-60.

50.

Recent epidemiological studies of the association between hormone replacement therapy and venous thromboembolism. A review.

Castellsague J, Pérez Gutthann S, García Rodríguez LA.

Drug Saf. 1998 Feb;18(2):117-23. Review.

PMID:
9512918

Supplemental Content

Loading ...
Support Center